Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
108.17
+2.05 (1.93%)
At close: Aug 21, 2026, 4:00 PM EDT
108.17
0.00 (0.00%)
After-hours: Aug 21, 2026, 6:27 PM EDT
Halozyme Therapeutics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Halozyme Therapeutics stock has a consensus rating of "Buy" and an average price target of $99.56. The average 1-year stock price forecast is 7.96% lower than the current stock price, while the lowest is $70 (-35.29%) and the highest is $115 (+6.31%).
Price Target: $99.56 (-7.96%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Halozyme Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Total | 9 | 9 | 10 | 10 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $115 | Buy | Reiterates | $115 | +6.31% | Aug 17, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $93 → $105 | Buy | Reiterates | $93 → $105 | -2.93% | Aug 7, 2026 |
| Leerink Partners | Leerink Partners | Buy Upgrades $83 → $110 | Buy | Upgrades | $83 → $110 | +1.69% | Aug 7, 2026 |
| Citizens JMP | Citizens JMP | Buy Maintains $92 → $93 | Buy | Maintains | $92 → $93 | -14.02% | Aug 7, 2026 |
| Wells Fargo | Wells Fargo | Hold Reiterates $75 → $95 | Hold | Reiterates | $75 → $95 | -12.18% | Aug 7, 2026 |
Financial Forecast
Revenue This Year
1.85B
from 1.40B
Increased by 32.73%
Revenue Next Year
2.05B
from 1.85B
Increased by 10.62%
EPS This Year
8.58
from 4.15
Increased by 106.67%
EPS Next Year
10.39
from 8.58
Increased by 21.17%
EPS and Forward PE are based on non-GAAP adjusted numbers.